Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
NaNoticsNaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
NaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
Publication Number
US-10653790-B2
Publication Date
2020-05-19
Expiration Date
Abstract
The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells.
Core Innovation
The invention relates to a particle comprising a first plurality of reactive groups. Each reactive group selectively reacts with a first agent comprising a first predetermined functional group, and after the first agent is linked through the first predetermined functional group, the first agent has a reduced ability to bind to a molecule on the surface of a cell.
The particle further comprises a plurality of coating molecules, wherein the plurality of coating molecules comprises a polymer. The longest dimension of the particle is about 50 nm to about 5 m.
In related embodiments, the particle includes structural arrangements such as a porous particle with outer and inner surfaces, where the reactive groups are disposed on inner pore walls. The particle can also include interior and exterior surface concepts and protective shielding to inhibit binding.
Claims Coverage
The document provides one independent claim. The claim covers a particle configured to selectively link a first agent via a first predetermined functional group while reducing the agents ability to bind a cell-surface molecule, with further claim elements defining polymer coating molecules and a particle size range.
Selectively linked first agent with reduced cell-surface binding ability
A particle comprising a first plurality of reactive groups, wherein each reactive group selectively reacts with a first agent comprising a first predetermined functional group, and wherein after the first agent is linked through the first predetermined functional group, the first agent has a reduced ability to bind to a molecule on the surface of a cell.
Polymer coating molecules and particle size range
The particle comprises a plurality of coating molecules, wherein the plurality of coating molecules comprises a polymer, and the longest dimension of the particle is about 50 nm to about 5 m.
Overall, claim coverage centers on configuring reactive groups to selectively couple an agent through predetermined functional groups while reducing subsequent binding to cell-surface molecules, together with a polymer-containing coating and a defined particle size range.
Stated Advantages
Reduced ability of the linked first agent to bind to a molecule on the surface of a cell.
Coating molecules comprising a polymer enable steric effects that prevent binding to a cell surface molecule.
Documented Applications
Examples involving cytokines/receptor-type agents on nanoparticle surfaces, including macrophage recruitment/evasion via coatings.
Interested in licensing this patent?